Results 71 to 80 of about 67,431 (260)

Post‐Translational Modifications of Key Proteins in Hematologic Malignancies: Carcinogenic Mechanisms, Biomarker Potential, and New Therapeutic Strategies

iLABMED, EarlyView.
This article reviews the pivotal role of post‐translational modifications of proteins in the development and progression of hematologic malignancies, and explores their clinical translation potential as novel biomarkers and therapeutic targets. ABSTRACT Post‐translational modifications (PTMs) of proteins have emerged as critical regulators in the ...
Yuxuan Han, Chaowei Zhang, Weiyi Yao, Qing Hong, Xinyu Tang, Yanan Zhu, Na Chen   +6 more
wiley   +1 more source

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Journal of Community Hospital Internal Medicine Perspectives, 2018
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias, Shahzeem Bhayani, David J. Gemmel, Sudershan K. Garg   +3 more
doaj   +1 more source

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Proteomes, 2014
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases.
Katerina Arvaniti, Anastasia Papadioti, Maria Kinigopoulou, Vassiliki Theodorou, Konstantinos Skobridis, Georgios Tsiotis   +5 more
doaj   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

Journal of Applied Toxicology, EarlyView.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü, Münevver Baran, Miyase Gözde Gündüz, Şengül Dilem Doğan   +3 more
wiley   +1 more source

Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase‐Deficient Gastrointestinal Stromal Tumors

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives Succinate dehydrogenase‐deficient (SDH‐deficient) gastrointestinal stromal tumors (GIST) are characterized by variable disease biology with poor responses to traditional tyrosine kinase inhibitors. The role of surgical intervention has been highly debated.
Katherine Y. Chen, Mark Antkowiak, Ashwyn K. Sharma, Robert Mallory, Adam M. Burgoyne, Paul T. Fanta, Jason K. Sicklick   +6 more
wiley   +1 more source

Performance of Survival Prediction Tools in Patients With Gastrointestinal Stromal Tumors: A Systematic Review and Meta‐Analysis

Journal of Surgical Oncology, EarlyView.
ABSTRACT Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. We conducted a systematic review and meta‐analysis of studies that developed, validated, or updated clinical prognostic tools to predict survival in adults with primary GIST, identifying 47 eligible studies (38 development and 9 ...
Alice Zhu, Chloe Wong, Neill K. J. Adhikari, Ka Yan Ip, Alyson Mahar, Amy T. Hsu, Julie Hallet, Natalie Coburn   +7 more
wiley   +1 more source

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq, Abdul Qayyum, Mubashar Naqvi, Tariq Gill, Muhammad Khalid, Ammara Tahir, Abid Jamil, Ahmad Khalid, Mahwish Khan, Muhammad Ferhan, Ijaz Shah, Abid Taj, Weng Qin, Mudassar Iqbal, Muhammad Abbad, Aamer Aleem, Tanveer Akhtar, Zafar Iqbal, Najeeb ur-Rehman, Shahid Baig   +19 more
core  

İmatinib: Mechanisms of Action and Mechanisms of Resistance Development

, 2012
İmatinib is a specific drug which was developed for the treatment of chronic myelogenous leukemia (KML) and is the pioneer drug in this area. İmatinib mesylate (Glivec) is a derivative of 2-phenylaminopyrimidine.
M. Merve Tuğlu, Mehmet Melli
core   +1 more source

Nephrogenic Systemic Fibrosis: A Rare Contemporary Case After a Decade of Declining Incidence

JEADV Clinical Practice, EarlyView.
ABSTRACT Nephrogenic systemic fibrosis (NSF) is a rare fibrosing disorder associated with exposure to gadolinium‐based contrast agents in patients with renal impairment. Although its incidence has markedly declined since the restriction of high‐risk linear gadolinium agents, sporadic cases may still occur.
Marta Sánchez Díaz, Alberto Andamoyo Castañeda, Pedro José Navarro Guillamón, Elena Gallego Domínguez, Jorge Alonso Suárez Pérez, Enrique Herrera Acosta   +5 more
wiley   +1 more source

RNA profiling and immunohistochemistry analyses of circRNAs in imatinib-resistant gastrointestinal stromal tumors

Journal of Translational Medicine
Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal sarcomas of the upper digestive tract. Imatinib is the first-line therapy for patients with metastatic or unresectable GISTs.
Hanxing Tong, Ning Jia, Wenyang Li, Jingjing Xu, Qiuyue Li, Xiaomeng He, Huaqin Sun, Christopher Corpe, Jin Wang   +8 more
doaj   +1 more source